This article summarized the latest R&D progress of Colecalciferol, the Mechanism of Action for Colecalciferol, and the drug target R&D trends for Colecalciferol.

Alzheon, Inc. reported that their Phase 2 study of ALZ-801 resulted in reduced neural degradation, stabilized brain function, and improved cognition in initial Alzheimer's patients with the apolipoprotein ε4 allele over two years of treatment.

This article summarized the latest R&D progress of Camptothecin, the Mechanism of Action for Camptothecin, and the drug target R&D trends for Camptothecin.

To acquire patent data related to a delineated antibody sequence, the Patsnap Bio Sequence Database is an optimal resource for conducting a systematic search.

This article summarized the latest R&D progress of Baicalin, the Mechanism of Action for Baicalin, and the drug target R&D trends for Baicalin.

IQ32 Bio and Horizon Therapeutics initiated a Phase 2 trial for bempikibart's effectiveness against severe adult alopecia areata.

This article summarized the latest R&D progress of Artesunate, the Mechanism of Action for Artesunate, and the drug target R&D trends for Artesunate.

Cyclooxygenase, also known as Prostaglandin-endoperoxide Synthase, is a bifunctional enzyme with both cyclooxygenase and peroxidase activity.

This article summarized the latest R&D progress of Amobarbital, the Mechanism of Action for Amobarbital, and the drug target R&D trends for Amobarbital.

At the 2023 IASLC World Lung Cancer Conference in Singapore, RS Oncology shared a first-of-its-kind PRX3 inhibitor, RSO-021's potential to combat swift mesothelioma tumor progression.

This article summarized the latest R&D progress of Salicylamide, the Mechanism of Action for Salicylamide, and the drug target R&D trends for Salicylamide.

Catechol O-methyltransferase (COMT) is an enzyme responsible for the O-methylation of endogenous neurotransmitters, xenobiotics, and hormones with catechol structures.